Home > Healthcare > Pharmaceuticals > Vaccines > Combination Vaccines Market

Combination Vaccines Market Trends

Report ID: GMI6086
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Combination Vaccines Industry Trends

The increasing prevalence of infectious diseases, such as influenza, hepatitis, and diphtheria is expected to boost the combination vaccines market expansion. Also, according to the Pan American Health Organization report, approximately 10,000 new hepatitis B infections occur each year, and 23,000 deaths. As infectious diseases continue to pose significant health risks, there is a growing need for effective vaccination strategies, thereby augmenting the market growth. Furthermore, the increasing awareness among population pertaining to the benefits of combination vaccines including hepatitis B vaccine in managing infectious diseases will create a favourable market opportunity for businesses operating in the combination vaccines sector.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of combination vaccines was worth USD 4.6 billion in 2022 and is projected to register 10.9% CAGR from 2023 to 2032 attributed to the increasing emphasis on preventive healthcare globally along with the rising focus on vaccination as a crucial preventive measure.

Combination vaccines industry size from the conjugate technology segment is estimated to cross USD 5.1 billion by 2032 owing to the massive R&D investments by pharmaceutical companies and government organizations.

North America held 40.8% of the global industry share in 2022 and is anticipated to exhibit robust growth till 2032 driven by the presence of favorable regulatory environment and the high prevalence of infectious diseases across the region.

Leading combination vaccines companies are Sanofi Pasteur, GlaxoSmithKline (GSK), Merck & Co., Inc., Panacea Biotec, Sinovac Biotech, and Serum Institute of India, among others.